Status:
TERMINATED
A One Year Clinical Trial Assessing the Usefulness and Safety of Inhaled Insulin in Diabetics With COPD
Lead Sponsor:
Pfizer
Conditions:
Diabetes Mellitus
Chronic Obstructive Pulmonary Disease
Eligibility:
All Genders
30-77 years
Phase:
PHASE3
Brief Summary
A One Year Clinical Trial Assessing the Usefulness and Safety of Inhaled Insulin in Diabetics with Chronic Obstructive Pulmonary Disease.
Detailed Description
Pfizer announced in October 2007 that it would stop marketing Exubera. At that time recruitment for study A2171030 was placed on hold. Nektar, the company from which Pfizer licensed Exubera, announced...
Eligibility Criteria
Inclusion
- Diabetes Mellitus (Type 1 or Type 2) currently controlled with injected insulin
- Prior smokers with a fixed airflow obstruction at screening (FEV1/FVC \< 70%) and FEV1 \< 80% predicted and/or a history of chronic productive cough.
Exclusion
- Poorly controlled, unstable or steroid-dependent COPD, insulin pump therapy, active smoking
Key Trial Info
Start Date :
January 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2008
Estimated Enrollment :
105 Patients enrolled
Trial Details
Trial ID
NCT00138671
Start Date
January 1 2003
End Date
September 1 2008
Last Update
February 2 2010
Active Locations (88)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Glendale, Arizona, United States, 85306
2
Pfizer Investigational Site
Peoria, Arizona, United States, 85381
3
Pfizer Investigational Site
Phoenix, Arizona, United States, 85004
4
Pfizer Investigational Site
Phoenix, Arizona, United States, 85006